Halberd Corporation (OTC PINK:HALB) has achieved remarkable success with its patent-pending extracorporeal laser eradication process. Through an experimental process conducted by Dr. Chester Cooper and Dr. W. Gregg Sturrus of Youngstown State University (YSU) with student scholar lab assistants, Halberd has been able to successfully eliminate even the most resistant strains of bacteria, such as Escherichia coli and other Gram-Negative bacteria, provided by the Centers for Disease Control and Prevention (CDC).
Dr. Cooper, Professor at the Department of Chemical and Biological Sciences at YSU, is thrilled with the students’ progress! With appropriate training, they have become incredibly adept at combining the necessary antibodies with metallic nanoparticles and the bacteria under test for laser exposure in Dr. Sturrus’ lab. Furthermore, their meticulous preparation of the various bacterial strains for laser exposure, as well as the assessment of bacteria elimination after laser exposure, is remarkable. It’s even more exciting that the same antibody can be used to eliminate a variety of bacteria due to its affinity to a wide range of bacteria.
The Halberd research project has been an eye-opening experience for the students involved, as they are able to apply the concepts they learn in the classroom to a real-world application. Through laser micro-heating, they are able to extracorporeally eradicate target antigens. Dr. Sturrus, Chair and Professor of the Physics, Astronomy Geology and Earth Science Department, is amazed by the enthusiasm and dedication of the students involved in the project and has never seen anything like it.
Halberd’s revolutionary technology is revolutionizing the future of medicine worldwide. Through our patented process, we have been able to successfully eradicate a wide range of antibiotic-resistant bacteria, including Escherichia coli, Candida auris, Salmonella, Shigella, pneumococcus, and more – all within ten minutes or less of exposure to laser emissive energy. This is in stark contrast to the current standard of care of oral or injected antibiotic administration for up to ten days of required treatment. We have yet to encounter an antigen that we have not been able to successfully eradicate, and we have the flexibility of a multiplicity of eradication methods – laser, chemical bonding and radio frequency, each safely administered extracorporeally.
About Halberd Corporation
Halberd Corporation (OTC PINK:HALB) is a publicly traded company with a bright future. After a major restructuring in April 2020, Halberd has obtained exclusive worldwide rights to no less than four issued patents and filed an additional twenty related patent applications to enrich the company’s value and attract potential partners. With its relentless commitment to innovation and growth, Halberd is sure to make waves on the OTC Market.